mRNA Vaccines & Therapeutics Market is valued at USD 77.66 Billion in 2022 and expected to reach USD 327.77 Billion by 2029 with a CAGR of 22.84% over the forecast period.
Increasing cases of Covid-19 & growing demand for Covid-19 vaccine, rising prevalence of chronic diseases and viral infections and growing number of research & development activities are the major factors driving the growth of the Global mRNA Vaccines & Therapeutics Market.
mRNA vaccines tricks the body to produce some of the viral proteins itself. As vaccination has had a tremendous impact on global health and the quality of human life, scientists have developed a new type of vaccine that uses a molecule called messenger RNA or mRNA rather than part of an actual bacteria or virus. These mRNA vaccines also have remarkable possibility to fight against viral diseases and cancer due to its superiorities in efficacy, safety and industrial production. The recent advancements in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad range of applications.
Thus, new technological innovations such as increased stability, translation and delivery methods have enabled messenger RNAs to become a promising therapeutic tool. Indeed, mRNA vaccines have created new fields in the biopharmaceutical industry and have become a significant type of therapeutic. These mRNA vaccines are encouraging next-generation vaccines that have introduced a new age in vaccinology. In addition, RNA therapeutics is the rapidly expanding category of drugs for many diseases, which will change the standard of care and represent personalized medicine. The mRNA vaccines and therapeutics incorporates the desirable immunological properties and these are produced in laboratories using mammalian cells.
The nature of mRNA technology permits rapid enhancement with almost limitless combinations of byproducts in the race of optimization. RNA vaccines provide multiple advantages as compared to other vaccines such as DNA vaccines in terms of administration, production and safety and also they have been shown to be auspicious in clinical trials involving humans, which have increased the demand of mRNA vaccine & therapeutic. In 1961 when Brenner and colleagues have started working on the foundation of the concept of mRNA as a therapeutic agent the use of mRNA in biology was started.
Covid 19 has shown a positive impact on the growth of global mRNA vaccines & therapeutics market as this mRNA technology finds its applications in the Covid-19 vaccine including many other diseases. The market for mRNA is mostly driven by the Covid-19 vaccine as COVID-19 mRNA vaccines give instructions for human cells to make a harmless piece called the “spike protein” and this spike protein is found on the surface of the virus that causes COVID-19. With the mutation of the coronavirus and possible spread of variants of the virus, the mRNA companies are actively engaged in developing next generation vaccines for Covid-19.
The first two vaccines i.e. Vaccines made by Pfizer-BioNTech and Moderna are authorized for use in the United States use messenger RNA, or mRNA, technology. Those two shots were already viewed as a preferred choice among wealthy countries. The United States and European Union are pushing to stock up on even more of the mRNA vaccines. Japan is also working to secure about 100 million doses of Pfizer’s shot. This shows the positive impact of Covid 19 on the market.
Global mRNA vaccines & therapeutics market is segmented in terms of type, end-user and region & country level. On the basis of type, the global mRNA vaccines & therapeutics market is classified into standardization of cancer treatment mRNA vaccine, individualized cancer treatment mRNA vaccine, infectious disease treatment mRNA vaccine and infection prevention mRNA vaccine. On the basis of end-user, the market has been divided into infectious disease, cancer and others.
The regions covered in global mRNA vaccines & therapeutics Market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the global mRNA vaccines & therapeutics market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some of The Key Players of Global mRNA Vaccines & Therapeutics Market are -
On the other hand, competition in the global mRNA vaccines & therapeutics market is high due to potential demand of mRNA vaccine & therapeutic in near future, intense research & development activities, presence of few market players, relatively new technological application, high investment, increasing number of mergers& acquisitions of major pharmaceutical players to enter into this market as well as to compete for innovating new vaccines and therapeutics for chronic diseases. Other than that, some market players are involved in partnership and collaboration activity to remain competitive in healthcare industry.
For instance; On May 1st, 2020, Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Lonza Ltd. announced a 10-year strategic collaboration agreement to make larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and other Moderna products in the future.
Globally, the COVID-19 pandemic has led to a dramatic loss of human life and presents an unprecedented challenge to public health, food systems and the world of work. For instance; according to World Health Organization, On August 5th, the cumulative number of COVID-19 cases globally surpassed 200 million, just six months after reaching 100 million cases. So, there is increasing demand for vaccine owing to the growing prevalence of Covid-19 cases. The WHO and its partners are seeking to produce COVID-19 vaccines by using mRNA technology and scale up manufacturing to increase global access to these critical tools to bring the pandemic under control.
In addition, many players are collaborating to develop the mRNA based Covid-19 vaccine. For instance; on February 3rd, 2021, GSK and CureVac collaborated to develop next generation mRNA COVID-19 vaccines. In addition, increasing number of product launches in the market is also supplementing the market growth. For instance; on November 9th, 2020 Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2.
Also, vaccination is an important strategy to prevent the transmission of various infectious diseases such as rubella, smallpox, measles, mumps, and recently, coronavirus 2019 disease (COVID-19). The preclinical and clinical trials have shown that mRNA vaccines provide a safe and long-lasting immune response in animal models and humans. So there has been a broad interest in RNA-based technologies for the development of prophylactic and therapeutic vaccines. In addition, the mRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production as these mRNA vaccines are coupled with immunologic adjuvant and various delivery strategies. Also, new advancements enable mRNA-based vaccines a priority in the treatment of tumors, viral and chronic diseases.
This shows that there are a few crucial benefits of using mRNA vaccines versus other types of vaccines as mRNA vaccines has a wide variety of application to cure various chronic diseases. Thus, many companies are working on to develop the new advanced mRNA vaccine to prevent diseases. For instance; On July 27th, 2021; BioNTech Company has announced that it is planning to use the mRNA technology to develop a first of its kind vaccine for malaria, with an end of 2022 target to begin clinical testing.
Furthermore, increasing number of cases of pediatric respiratory diseases and hemoglobinopathy and its various advantages are also supplementing the market growth mainly for mRNA therapeutics. Respiratory problems in children, especially in new-borns and require immediate treatment as the disease can progress more rapidly in young children than in adults. The most common cause of heart disease in children is the respiratory system. Asthma, tuberculosis, bronchiectasis and bronchopulmonary dysplasia are acute respiratory diseases in children. Gene replacement could be an alternative route and possibly benefit in these patients. One such target for gene therapy would be to influence Th2 cytokine reactions by inducing regulatory T cells. Administration of modified Foxp3 mRNA in a time- and site-specific fashion in murine lungs prevents allergic asthma in vivo, while suppressing Th2 responses.
Moreover, rising number of research and development activities are expected to provide new opportunities for the market growth in forecast period.However, potential side effects of vaccine, high cost of product development and stringent process of regulatory approvals may Hamper the Market Growth.
Over the period, major technological innovation and research investment have enabled mRNA to become a promising therapeutic tool in the fields of vaccine development and protein replacement therapy. mRNA holds the potential to revolutionize vaccination, protein replacement therapies, and the treatment of genetic diseases. In recent years, numbers of infectious diseases are rapidly increasing which increase the need for research and development in pharmaceutical field. RNA vaccines are being explored as a way to more rapidly and cheaply produce vaccines for these diseases, particularly in response to emerging outbreaks. Clinical trials have been carried out and ongoing on mRNA vaccines for influenza, cytomegalovirus, HIV-1, rabies and Zika virus.
Additionally, rapidly increasing investment in the COVID-19 vaccine research will also generate an opportunity for the market growth. For example; Moderna Company announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 and has also begun dosing participants.mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center.
The global mRNA vaccines & therapeutics market is classified into North America, Europe, Asia Pacific Latin America and Middle East & Africa. North America region is expected to dominate the global mRNA vaccines & therapeutics market due to factors such as increasing demand for mRNA vaccines for COVID-19, presence of prominent players operating in the U.S. and growing need to develop transformative therapeutics in this region. The pandemic has disrupted lives, pushed the hospital system to its capacity, and created an economic slowdown in this region.
For instance, according to World Health Organization in United States of America, from January 3RD, 2020 to August 11th, 2021, there have been 35,824,366 confirmed cases of COVID-19 with 612,973 deaths are reported. In addition, increasing prevalence of chronic diseases and various infectious diseases are the major health issues in North America. For example; according to centers for disease control and prevention; more than 859,000 Americans die of heart disease every year. And cancer is the second leading cause of death in the United States, more than 1.6 million people are diagnosed with cancer, and almost 600,000 die from it.
Also Asia-pacific region is expected to witness a lucrative growth in the global mRNA vaccines & therapeutics market due to the increasing cases of Covid-19, growing demand for mRNA vaccines, rising prevalence of cancer in this region. For example; in India, as of August 12th, 2021; total number of active cases of covid-19 are 3,92,449.
As Asian countries such as Australia, South Korea and Singapore are among the governments now racing to establish facilities to develop the new vaccine for preventing Covid-19 and in the process harness a potentially game-changing technology such as mRNA in the fight against disease. Countries have realised that they are highly dependent on vaccine supplies from elsewhere and they are finding it difficult to get what they need to deal with their public health crisis. So, they are trying to have a sovereign capacity to make vaccines against Covid-19.
Government of Canada Announced Agreement with Leading COVID-19 Vaccine Developer Moderna, Inc. to Build mRNA Vaccine Facility in Canada
On August 10th, 2021; the Honorable François-Philippe Champagne, Minister of Innovation, Science and Industry has announced a major milestone in Canada’s strategy that to rebuild the biomanufacturing and life sciences sector. The Government of Canada has established this memorandum of understanding (MOU) with leading COVID-19 vaccine developer Moderna, Inc. to build a state-of-the-art mRNA vaccine production facility in Canada. As a decades-long decline in the sector left Canada without the large-scale and flexible biomanufacturing capacity necessary to quickly produce a COVID-19 vaccine when the pandemic hit. This is why the government has worked tirelessly to rebuild Canada’s domestic biomanufacturing sector by focusing on both quick strategic actions and a long‑term vision.
Sanofi Decided to Acquire Translate Bio to Advance the Deployment of mRNA Technology across Vaccines and Therapeutics Development
On August 3rd, 2021; the Sanofi company has entered into a definitive agreement with Translate Bio as part of its endeavor for accelerating the application of messenger RNA (mRNA) to develop therapeutics and vaccines. Translate Bio is a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for about $38.00 per share in cash which represents a total equity value of approximately $3.2 billion. The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.
BioNTech is Planning to Develop First mRNA-Based Vaccine for Malaria by 2022
On July 27th, 2021; BioNTech Company has announced that it is planning to use the mRNA technology to develop a first of its kind vaccine for malaria, with an end of 2022 target to begin clinical testing. After the deal with the Covid-19 pandemic with its mRNA vaccine, the company is planning to use the same technology for developing a first of its kind vaccine for malaria with an end of 2022 target to begin clinical testing. This malaria project of the company is part of the ‘eradicateMalaria’ initiative, led by the kENUP Foundation to accelerate the eradication of the mosquito-borne disease. The efforts are supported by the World Health Organization (WHO) and the Africa Centers for Disease Control and Prevention (Africa CDC).
2016 - 2021
2022 - 2029
Market Size in 2022:
USD 77.66 Billion
Base year considered
Forecast Period CAGR %:
Market Size Expected in 2029:
USD 327.77 Billion
Tables, Charts & Figures:
mRNA Vaccines & Therapeutics Companies
Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, In-Cell-Art, Etherna, Ethris, AstraZeneca Plc, Boehringer Ingelheim, GlaxoSmithKline, Crispr Therapeutics, Intellia Therapeutics, Arcturus Therapeutics, Argos Therapeutics Inc., Daiichi Sankyo, Gennova Biopharmaceuticals, Pantherna Therapeutics, Tiba Biotech, and others.
By Type, By End User
North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®